Endoscopic Submucosal Dissection Versus Esophagectomy for Early Esophageal Carcinoma
- Disease/Condition
- Esophageal Cancer
- Drug/Device/Intervention
- Endoscopic submucosal dissection
- Study type
- Observational
- Intervention type
- procedure
- Primary sponsor
- Changhai Hospital
- Location
- Shanghai, China
- Phase
- N/A
- Start date
- Jan 01, 2011
- End date
- Jan 01, 2023
- Enrollment
- 191 participants
overall survival (OS),Disease specific survival (DSS),Recurrence free survival (RFS)
Endoscopic submucosal dissection (ESD) is a minimally invasive alternative to esophagectomy
 for early esophageal squamous cell carcinoma (EESCC), The data of EESCC patients who received
 ESD or esophagectomy were retrospectively analyzed,The aim of this study was to compare the
 efficacy and safety of ESD and esophagectomy in EESCC,Risk factors affecting the prognosis of
 patients with early esophageal squamous cell carcinoma were analyzed.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06060106
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06060106 through Pure Global AI's free database. This phase not specified trial is sponsored by Changhai Hospital and is currently Completed. The study focuses on Esophageal Cancer. Target enrollment is 191 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.